Karin Eastham has served on our board since September 2019. Ms. Eastham has over 35 years of experience in financial and operations management, primarily in life sciences companies. Ms. Eastham serves as a director for 3 additional public biotechnology companies, Nektar Therapeutics, Geron Corporation, and Veracyte, Inc. Her former public directorships include Illumina, Inc., MorphoSys AG (based in Munich, Germany), and Amylin Pharmaceuticals.  Ms. Eastham’s career includes her service as Executive Vice President and Chief Operating Officer and Trustee of the Burnham Institute for Medical Research. She also served as Senior Vice President, Finance, Chief Financial Officer, and Secretary of Diversa Corporation. She held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at BoehringerMannheim Diagnostics.  Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.